Automatic prediction of hepatic arterial infusion chemotherapy response in advanced hepatocellular carcinoma with deep learning radiomic nomogram
- PMID: 37498380
- DOI: 10.1007/s00330-023-09953-x
Automatic prediction of hepatic arterial infusion chemotherapy response in advanced hepatocellular carcinoma with deep learning radiomic nomogram
Abstract
Objectives: Hepatic arterial infusion chemotherapy (HAIC) using the FOLFOX regimen (oxaliplatin plus fluorouracil and leucovorin) is a promising option for advanced hepatocellular carcinoma (Ad-HCC). As identifying patients with Ad-HCC who would obtain objective response (OR) to HAIC preoperatively remains a challenge, we aimed to develop an automatic and non-invasive model for predicting HAIC response.
Methods: A total of 458 patients with Ad-HCC who underwent HAIC were retrospectively included from three hospitals (310 for training, 77 for internal validation, and 71 for external validation). The deep learning and radiomic features were extracted from the automatically segmented liver region on contrast-enhanced computed tomography images. Then, a deep learning radiomic nomogram (DLRN) was constructed by integrating deep learning scores, radiomic scores, and significant clinical variables with multivariate logistic regression. Model performance was assessed by AUC and Kaplan-Meier estimator.
Results: After automatic segmentation, only a few modifications were needed (less than 30 min for 458 patients). The DLRN achieved an AUC of 0.988 in the training cohort, 0.915 in the internal validation cohort, and 0.896 in the external validation cohort, respectively, outperforming other models in HAIC response prediction. Moreover, survival risk stratification was also successfully performed by the DLRN. The overall survival (OS) of the predictive OR group was significantly longer than that of the predictive non-OR group (median OS: 26.0 vs. 12.3 months, p < 0.001).
Conclusions: The DLRN provided a satisfactory performance for predicting HAIC response, which is essential to identify Ad-HCC patients for HAIC and may potentially benefit personalized pre-treatment decision-making.
Clinical relevance statement: This study presents an accurate and automatic method for predicting response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma, and therefore help in defining the best candidates for this treatment.
Key points: • Deep learning radiomic nomogram (DLRN) based on automatic segmentation of CECT can accurately predict hepatic arterial infusion chemotherapy (HAIC) response of advanced HCC patients. • The proposed prediction model can perform survival risk stratification and is an easy-to-use tool for personalized pre-treatment decision-making for advanced HCC patients.
Keywords: Decision-making; Deep learning; FOLFOX protocol; Hepatocellular carcinoma.
© 2023. The Author(s), under exclusive licence to European Society of Radiology.
Similar articles
-
A multitask deep learning radiomics model for predicting the macrotrabecular-massive subtype and prognosis of hepatocellular carcinoma after hepatic arterial infusion chemotherapy.Radiol Med. 2023 Dec;128(12):1508-1520. doi: 10.1007/s11547-023-01719-1. Epub 2023 Oct 6. Radiol Med. 2023. PMID: 37801197 Free PMC article.
-
A Contrast-Enhanced Ultrasound Cine-Based Deep Learning Model for Predicting the Response of Advanced Hepatocellular Carcinoma to Hepatic Arterial Infusion Chemotherapy Combined With Systemic Therapies.Cancer Sci. 2025 Jul;116(7):1930-1940. doi: 10.1111/cas.70089. Epub 2025 Apr 29. Cancer Sci. 2025. PMID: 40302359 Free PMC article.
-
A new prognostic model for predicting overall survival and progression-free survival in unresectable hepatocellular carcinoma treated with the FOLFOX-HAIC regimen based on patient clinical characteristics and blood biomarkers.BMC Cancer. 2025 Jan 21;25(1):112. doi: 10.1186/s12885-024-13390-4. BMC Cancer. 2025. PMID: 39838301 Free PMC article.
-
Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review.Expert Rev Anticancer Ther. 2024 Jun;24(6):423-434. doi: 10.1080/14737140.2024.2346624. Epub 2024 Apr 24. Expert Rev Anticancer Ther. 2024. PMID: 38651280 Review.
-
Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma.Asia Pac J Clin Oncol. 2010 Jun;6(2):80-8. doi: 10.1111/j.1743-7563.2010.01287.x. Asia Pac J Clin Oncol. 2010. PMID: 20565419 Review.
Cited by
-
Leveraging radiomics and AI for precision diagnosis and prognostication of liver malignancies.Front Oncol. 2024 May 8;14:1362737. doi: 10.3389/fonc.2024.1362737. eCollection 2024. Front Oncol. 2024. PMID: 38779098 Free PMC article. Review.
-
Research progress on machine algorithm prediction of liver cancer prognosis after intervention therapy.Am J Cancer Res. 2024 Sep 25;14(9):4580-4596. doi: 10.62347/BEAO1926. eCollection 2024. Am J Cancer Res. 2024. PMID: 39417194 Free PMC article. Review.
-
A deep learning model for personalized intra-arterial therapy planning in unresectable hepatocellular carcinoma: a multicenter retrospective study.EClinicalMedicine. 2024 Sep 5;75:102808. doi: 10.1016/j.eclinm.2024.102808. eCollection 2024 Sep. EClinicalMedicine. 2024. PMID: 39296944 Free PMC article.
-
Prognostication of Hepatocellular Carcinoma Using Artificial Intelligence.Korean J Radiol. 2024 Jun;25(6):550-558. doi: 10.3348/kjr.2024.0070. Korean J Radiol. 2024. PMID: 38807336 Free PMC article. Review.
-
Advancing Hepatocellular Carcinoma Management Through Peritumoral Radiomics: Enhancing Diagnosis, Treatment, and Prognosis.J Hepatocell Carcinoma. 2024 Nov 4;11:2159-2168. doi: 10.2147/JHC.S493227. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 39525830 Free PMC article. Review.
References
-
- Miller KD, Goding Sauer A, Ortiz AP et al (2018) Cancer statistics for Hispanics/Latinos, 2018. CA Cancer J Clin 6:425–445 - DOI
-
- Villanueva A (2019) Hepatocellular carcinoma. N Engl J Med 15:1450–1462 - DOI
-
- Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 3:209–249 - DOI
-
- Pinter M, Scheiner B, Peck-Radosavljevic M (2021) Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut 1:204–214 - DOI
-
- Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 10126:1163–1173 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials